Beta Bionics Inc (BBNX)
Beta Bionics Inc. is a commercial-stage medical device company focused on technologies intended to improve outcomes and daily management for people with insulin-requiring diabetes. Its lead product is the iLet Bionic Pancreas, an insulin delivery device cleared for use in adults and children six years of age and older with type 1 diabetes. The company is also developing several related programs, including Patch Pump, a skin-adherent insulin pump designed to deliver insulin without tubing, Bihormonal iLet, which is being developed to automate delivery of both insulin and glucagon, and iLet for people with insulin-dependent type 2 diabetes. Beta Bionics has collaboration and license agreements with Xeris Pharmaceuticals and Abbott Diabetes Care to support development and commercialization activities. The company was incorporated in 2015 and is headquartered in Irvine, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-BBNX
|
$14.13
|
-19.5% Downside
|
Overvalued
|
$19.80
|
12.8% Upside
|
Fair
|
Good
|
—
|
—
|
—
|
0.0%
|
July 29, 2026
|
-11.7x
|
2.9x
|
7.1x
|
794.1 M
|
546.9 M
|
0.9%
|
56.9%
|
13.0
|
—
|
92.0%
|
